Abstract 1189
Background
Venous thromboembolism (VTE) is frequently observed in patients with solid tumor. Previous report suggested that the prevalence of VTE varied among different ethnic groups. The objectives of this prospective observational study are to estimate the prevalence of VTE in Japanese patients with advanced solid tumor based on intensive screening, using CT scans, lower-extremity ultrasonography, and D-dimer testing.
Methods
Eight-hundred sixty Japanese patients were enrolled into this study. Adult (age ≥20 years) patients with metastatic or locally advanced solid tumor without anticoagulant therapy, who are planning to receive chemotherapy during 4 weeks, PS 0-2 were eligible in this study. Evaluations of VTE were performed at enrollment, 12 and 24 weeks. Primary endpoint was the prevalence of VTE for 24 weeks, and secondary endpoints included the incidence of VTE (at enrollment, 12 weeks, 24 weeks), VTE for 24 weeks by primary cancer site, symptomatic VTE for 24 weeks, pulmonary thromboembolism (PE), treatment of VTE.
Results
The median age was 68 years (range 28-96 years), 34% female, 46/45/8% performance status 0/1/2. Primary cancer site included lung (71%), gastrointestinal (GI) (15%), hepatobiliary and pancreatic (HP) (5%), and gynecological (3%). The prevalence of VTE for 24 weeks was 22.6% (95%CI: 19.8-25.5%). The incidences of VTE were 11.3% (97/858) at enrollment, 16.8% (134/799) at 12 weeks, 14.1% (101/716) at 24 weeks. Among 761 patients without VTE at enrollment, 97 (12.7%) showed VTE after the start of chemotherapy. The prevalence of VTE for 24 weeks was 24.1% in patients with lung, 17.7% with GI, 25.6% with HP, and 32.1% in gynecological cancer. Symptomatic VTE for 24 weeks was observed in 4.0%, and PE was in 1.0%. Treatment of anticoagulant for VTE was started in 15.0% (129/858) after enrollment in this study.
Conclusions
This prospective observational study showed that prevalence of VTE was relatively high in Japanese patients with advanced solid tumor under intensive screening, compared with previous reports. Although most of patients with VTE were asymptomatic, prophylactic anticoagulant therapies may be considered in this study population.
Clinical trial identification
UMIN000015243.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract